Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma

E.J.M. de Jong; Q.P. Janssen; T.F.A. Simons; M.G. Besselink; B.A. Bonsing; S.A.W. Bouwense; S.M.E. Geurts; M.Y.V. Homs; V.E. de Meijer; V.C.G. Tjan-Heijnen; H.W.M. van Laarhoven; L.B.J. Valkenburg-van Iersel; J.W. Wilmink; L.G. van der Geest; B.G. Koerkamp; J. de Vos-Geelen; Dutch Pancreatic Canc Grp

doi:10.1002/ijc.33916

Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma

E.J.M. de Jong, Q.P. Janssen, T.F.A. Simons, M.G. Besselink, B.A. Bonsing, S.A.W. Bouwense, S.M.E. Geurts, M.Y.V. Homs, V.E. de Meijer, V.C.G. Tjan-Heijnen, H.W.M. van Laarhoven, L.B.J. Valkenburg-van Iersel, J.W. Wilmink, L.G. van der Geest, B.G. Koerkamp, J. de Vos-Geelen^*, Dutch Pancreatic Canc Grp

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1654-1663
Number of pages	10
Journal	International Journal of Cancer
Volume	150
Issue number	10
Early online date	31 Dec 2021
DOIs	https://doi.org/10.1002/ijc.33916
Publication status	Published - 15 May 2022

Keywords

chemotherapy
pancreatic cancer
survival
PHASE-III TRIAL
OPEN-LABEL
CANCER
CHEMOTHERAPY
MULTICENTER
FOLFIRINOX
RESECTION
SURVIVAL
THERAPY
TRENDS

Access to Document

10.1002/ijc.33916

Cite this

de Jong, E. J. M., Janssen, Q. P., Simons, T. F. A., Besselink, M. G., Bonsing, B. A., Bouwense, S. A. W., Geurts, S. M. E., Homs, M. Y. V., de Meijer, V. E., Tjan-Heijnen, V. C. G., van Laarhoven, H. W. M., Valkenburg-van Iersel, L. B. J., Wilmink, J. W., van der Geest, L. G., Koerkamp, B. G., de Vos-Geelen, J., & Dutch Pancreatic Canc Grp (2022). Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. International Journal of Cancer, 150(10), 1654-1663. https://doi.org/10.1002/ijc.33916

de Jong, E.J.M. ; Janssen, Q.P. ; Simons, T.F.A. ; Besselink, M.G. ; Bonsing, B.A. ; Bouwense, S.A.W. ; Geurts, S.M.E. ; Homs, M.Y.V. ; de Meijer, V.E. ; Tjan-Heijnen, V.C.G. ; van Laarhoven, H.W.M. ; Valkenburg-van Iersel, L.B.J. ; Wilmink, J.W. ; van der Geest, L.G. ; Koerkamp, B.G. ; de Vos-Geelen, J. ; Dutch Pancreatic Canc Grp. / Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. In: International Journal of Cancer. 2022 ; Vol. 150, No. 10. pp. 1654-1663.

@article{991a9c6733604d52a9f0fc9bc658b272,

title = "Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma",

keywords = "chemotherapy, pancreatic cancer, survival, PHASE-III TRIAL, OPEN-LABEL, CANCER, CHEMOTHERAPY, MULTICENTER, FOLFIRINOX, RESECTION, SURVIVAL, THERAPY, TRENDS",

author = "{de Jong}, E.J.M. and Q.P. Janssen and T.F.A. Simons and M.G. Besselink and B.A. Bonsing and S.A.W. Bouwense and S.M.E. Geurts and M.Y.V. Homs and {de Meijer}, V.E. and V.C.G. Tjan-Heijnen and {van Laarhoven}, H.W.M. and {Valkenburg-van Iersel}, L.B.J. and J.W. Wilmink and {van der Geest}, L.G. and B.G. Koerkamp and {de Vos-Geelen}, J. and {Dutch Pancreatic Canc Grp}",

year = "2022",

month = may,

day = "15",

doi = "10.1002/ijc.33916",

language = "English",

volume = "150",

pages = "1654--1663",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley",

number = "10",

}

de Jong, EJM, Janssen, QP, Simons, TFA, Besselink, MG, Bonsing, BA, Bouwense, SAW, Geurts, SME, Homs, MYV, de Meijer, VE, Tjan-Heijnen, VCG, van Laarhoven, HWM, Valkenburg-van Iersel, LBJ, Wilmink, JW, van der Geest, LG, Koerkamp, BG, de Vos-Geelen, J & Dutch Pancreatic Canc Grp 2022, 'Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma', International Journal of Cancer, vol. 150, no. 10, pp. 1654-1663. https://doi.org/10.1002/ijc.33916

Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. / de Jong, E.J.M.; Janssen, Q.P.; Simons, T.F.A.; Besselink, M.G.; Bonsing, B.A.; Bouwense, S.A.W.; Geurts, S.M.E.; Homs, M.Y.V.; de Meijer, V.E.; Tjan-Heijnen, V.C.G.; van Laarhoven, H.W.M.; Valkenburg-van Iersel, L.B.J.; Wilmink, J.W.; van der Geest, L.G.; Koerkamp, B.G.; de Vos-Geelen, J.; Dutch Pancreatic Canc Grp.

In: International Journal of Cancer, Vol. 150, No. 10, 15.05.2022, p. 1654-1663.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma

AU - de Jong, E.J.M.

AU - Janssen, Q.P.

AU - Simons, T.F.A.

AU - Besselink, M.G.

AU - Bonsing, B.A.

AU - Bouwense, S.A.W.

AU - Geurts, S.M.E.

AU - Homs, M.Y.V.

AU - de Meijer, V.E.

AU - Tjan-Heijnen, V.C.G.

AU - van Laarhoven, H.W.M.

AU - Valkenburg-van Iersel, L.B.J.

AU - Wilmink, J.W.

AU - van der Geest, L.G.

AU - Koerkamp, B.G.

AU - de Vos-Geelen, J.

AU - Dutch Pancreatic Canc Grp

PY - 2022/5/15

Y1 - 2022/5/15

KW - chemotherapy

KW - pancreatic cancer

KW - survival

KW - PHASE-III TRIAL

KW - OPEN-LABEL

KW - CANCER

KW - CHEMOTHERAPY

KW - MULTICENTER

KW - FOLFIRINOX

KW - RESECTION

KW - SURVIVAL

KW - THERAPY

KW - TRENDS

U2 - 10.1002/ijc.33916

DO - 10.1002/ijc.33916

M3 - Article

C2 - 34935139

VL - 150

SP - 1654

EP - 1663

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -